Literature DB >> 11738228

Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME.

A P Coletta1, J G Cleland.   

Abstract

This article continues a series of reports updating recent research developments of particular interest to personnel involved in the treatment and management of patients with heart failure. This is a summary of selected presentations made at the Scientific Sessions of the XXIII Annual Congress of the European Society of Cardiology. Summaries of the following clinical studies are included: WARIS-II, ESCAMI, PAFAC, RITZ-I and TIME.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11738228     DOI： 10.1016/s1388-9842(01)00210-0

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


  17 in total

Review 1.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

2.  Right-sided heart failure: diagnosis and treatment strategies.

Authors:  Jennifer Cowger Matthews; Todd F Dardas; Michael P Dorsch; Keith D Aaronson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

3.  Effects of tolvaptan on dyspnoea relief from the EVEREST trials.

Authors:  Peter S Pang; Marvin A Konstam; Holly B Krasa; Karl Swedberg; Faiez Zannad; John E A Blair; Christopher Zimmer; John R Teerlink; Aldo P Maggioni; John C Burnett; Liliana Grinfeld; John Ouyang; James E Udelson; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2009-06-27       Impact factor: 29.983

Review 4.  Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence.

Authors:  Maya Guglin
Journal:  Curr Heart Fail Rep       Date:  2011-09

Review 5.  Management of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation.

Authors:  Anna Koulova; Alan L Gass; Saikrishna Patibandla; Chhaya Aggarwal Gupta; Wilbert S Aronow; Gregg M Lanier
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 6.  The disconnect between phase II and phase III trials of drugs for heart failure.

Authors:  Muthiah Vaduganathan; Stephen J Greene; Andrew P Ambrosy; Mihai Gheorghiade; Javed Butler
Journal:  Nat Rev Cardiol       Date:  2013-01-08       Impact factor: 32.419

7.  Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study.

Authors:  S K Prasad; H J Dargie; G C Smith; M M Barlow; F Grothues; B A Groenning; J G F Cleland; D J Pennell
Journal:  Heart       Date:  2005-12-09       Impact factor: 5.994

Review 8.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

Review 9.  Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond.

Authors:  Gad Cotter; Olga Milo; Beth A Davison
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 10.  Endothelin receptor antagonists in heart failure: current status and future directions.

Authors:  Georg Ertl; Johann Bauersachs
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.